-+ 0.00%
-+ 0.00%
-+ 0.00%

Liu Enyang, chief analyst of Pharmaceutical Biology at BOC Securities, said in an interview with the Securities Times reporter a few days ago that recently, the three quarterly reports of listed pharmaceutical companies revealed that judging from the performance of the pharmaceutical industry itself, sector fundamentals showed a trend of marginal improvement. Industries such as CXO, innovative drugs, medical devices, retail pharmacies and other industries have gradually emerged from early pressure, and the overall revenue and profit side of the industry have recovered. First, on the policy side, the country continues to support innovative pharmaceutical devices. While normalizing collection and medical insurance negotiations and fee control, it further distinguishes generic drugs from innovative drugs, and continues to increase support for original pharmaceutical research, innovation, and clinical value-oriented products. Second, BD's authorization to go overseas has evolved from an attempt by a few leading companies to a normalized commercialization path for domestic innovative companies. Domestic pharmaceutical companies produce a large number of high-quality candidates in cutting-edge fields such as oncology. Through an external licensing model, pipeline rights are transferred to large overseas pharmaceutical companies, and commercialization is completed with the clinical development capabilities and global sales networks of multinational companies. Finally, in the field of high-end medical devices and consumables, domestic enterprises continue to overcome technical barriers, and product performance and quality stability are gradually being compared to the international first-tier level. Import substitution is gradually advancing from low-end consumables to high-end equipment and high-value consumables. The share of domestic products continues to rise, and the share of domestic production in many segments has been overtaken.

Zhitongcaijing·11/16/2026 05:49:07
Listen to the news
Liu Enyang, chief analyst of Pharmaceutical Biology at BOC Securities, said in an interview with the Securities Times reporter a few days ago that recently, the three quarterly reports of listed pharmaceutical companies revealed that judging from the performance of the pharmaceutical industry itself, sector fundamentals showed a trend of marginal improvement. Industries such as CXO, innovative drugs, medical devices, retail pharmacies and other industries have gradually emerged from early pressure, and the overall revenue and profit side of the industry have recovered. First, on the policy side, the country continues to support innovative pharmaceutical devices. While normalizing collection and medical insurance negotiations and fee control, it further distinguishes generic drugs from innovative drugs, and continues to increase support for original pharmaceutical research, innovation, and clinical value-oriented products. Second, BD's authorization to go overseas has evolved from an attempt by a few leading companies to a normalized commercialization path for domestic innovative companies. Domestic pharmaceutical companies produce a large number of high-quality candidates in cutting-edge fields such as oncology. Through an external licensing model, pipeline rights are transferred to large overseas pharmaceutical companies, and commercialization is completed with the clinical development capabilities and global sales networks of multinational companies. Finally, in the field of high-end medical devices and consumables, domestic enterprises continue to overcome technical barriers, and product performance and quality stability are gradually being compared to the international first-tier level. Import substitution is gradually advancing from low-end consumables to high-end equipment and high-value consumables. The share of domestic products continues to rise, and the share of domestic production in many segments has been overtaken.